Lyme disease DNA vaccine - Vical/Aventis Pasteur

Drug Profile

Lyme disease DNA vaccine - Vical/Aventis Pasteur

Latest Information Update: 15 May 2001

Price : $50

At a glance

  • Originator Vical
  • Class Bacterial vaccines; DNA vaccines; Gene therapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Lyme disease

Most Recent Events

  • 15 May 2001 Discontinued-Preclinical for Lyme disease in USA (Unknown route)
  • 24 Dec 1999 Pasteur Mérieux Connaught is now a subsidiary of Aventis and its new name is Aventis Pasteur
  • 19 Mar 1997 Animal studies have been added to the Bacterial Infections immunogenicity section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top